Labeled Abiraterone. A steroidal cytochrome P 450 17a-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer.Form:White to Off-White SolidMelting Point:213-215°CSolubility:Methanol